Ishara Investments LP
13F Reported Value
ⓘ$136.1M
Holdings
41
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Ishara Investments LP disclosed 41 positions worth $136.1M in its Form 13F-HR for Q2 2026, led by $ACAD (ACADIA PHARMACEUTICALS INC) at 7.6% of the equity portfolio, followed by $XERS and $BMRN. During the quarter the fund opened 16 new positions and exited 12 — including a new stake in $AGIO and a full exit from $PRAX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Ishara Investments LP’s Form 13F-HR filing with the SEC under CIK 2111609.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 67.8#344
Quality
$10.4M410,000 sh - 56.5#1,162
Quality
$9.7M1,230,000 sh - 58.2#1,030
Quality
$8.2M143,500 sh - $7.5M22,550 sh
- 34.2
Quality
$6.8M205,000 sh - 26.9
Quality
$6.1M164,000 sh - 39.4
Quality
$5.5M51,250 sh - 25.5
Quality
$5.4M143,500 sh - 11.6
Quality
$5.0M1,025,000 sh - —
Quality
$4.8M82,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 ACADIA PHARMACEUTICALS INC$ACAD | 67.8#344 | $10.4M | 410,000 |
 Xeris Biopharma Holdings, Inc.$XERS | 56.5#1,162 | $9.7M | 1,230,000 |
 BIOMARIN PHARMACEUTICAL INC$BMRN | 58.2#1,030 | $8.2M | 143,500 |
 Praxis Precision Medicines, Inc.$PRAX | — | $7.5M | 22,550 |
 Ultragenyx Pharmaceutical Inc.$RARE | 34.2 | $6.8M | 205,000 |
 AGIOS PHARMACEUTICALS, INC.$AGIO | 26.9 | $6.1M | 164,000 |
 INSMED Inc$INSM | 39.4 | $5.5M | 51,250 |
 Crinetics Pharmaceuticals, Inc.$CRNX | 25.5 | $5.4M | 143,500 |
 Zentalis Pharmaceuticals, Inc.$ZNTL | 11.6 | $5.0M | 1,025,000 |
 Vaxcyte, Inc.$PCVX | — | $4.8M | 82,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Ishara Investments LP's 41 positions.
Showing top 10 of 41 holdings.
Sector Allocation
Healthcare
$136.1M
Full Holdings — Ishara Investments LP (Q2 2026)
All 41 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ACAD | ACADIA PHARMACEUTICALS INC | $10.4M | 7.6% | +233% | 67.8 |
| 2 | $XERS | Xeris Biopharma Holdings, Inc. | $9.7M | 7.2% | +20% | 56.5 |
| 3 | $BMRN | BIOMARIN PHARMACEUTICAL INC | $8.2M | 6.0% | +75% | 58.2 |
| 4 | $PRAX | Praxis Precision Medicines, Inc. | $7.5M | 5.5% | +0% | — |
| 5 | $RARE | Ultragenyx Pharmaceutical Inc. | $6.8M | 5.0% | +18% | 34.2 |
| 6 | $AGIO | AGIOS PHARMACEUTICALS, INC. | $6.1M | 4.5% | NEW | 26.9 |
| 7 | $INSM | INSMED Inc | $5.5M | 4.0% | NEW | 39.4 |
| 8 | $CRNX | Crinetics Pharmaceuticals, Inc. | $5.4M | 4.0% | NEW | 25.5 |
| 9 | $ZNTL | Zentalis Pharmaceuticals, Inc. | $5.0M | 3.6% | -17% | 11.6 |
| 10 | $PCVX | Vaxcyte, Inc. | $4.8M | 3.5% | +43% | — |
| 11 |  $ANNX | Annexon, Inc. | $4.7M | 3.4% | +371% | — |
| 12 |  $TVTX | Travere Therapeutics, Inc. | $4.7M | 3.4% | -26% | 56.6 |
| 13 |  $TNXP | Tonix Pharmaceuticals Holding Corp. | $4.3M | 3.2% | NEW | 26.5 |
| 14 |  $BBIO | BridgeBio Pharma, Inc. | $4.3M | 3.1% | NEW | 36.9 |
| 15 |  $AXSM | Axsome Therapeutics, Inc. | $4.0M | 3.0% | -60% | 40.8 |
| 16 |  $CTNM | Contineum Therapeutics, Inc. | $3.4M | 2.5% | +44% | — |
| 17 |  $LXRX | LEXICON PHARMACEUTICALS, INC. | $3.1M | 2.2% | +41% | 33.7 |
| 18 |  $KURA | Kura Oncology, Inc. | $3.0M | 2.2% | NEW | 27.6 |
| 19 |  $DBVT | DBV Technologies S.A. | $3.0M | 2.2% | +80% | — |
| 20 |  $GMAB | GENMAB A/S | $2.8M | 2.1% | +25% | 77.9 |
| 21 |  $CYTK | CYTOKINETICS INC | $2.8M | 2.0% | NEW | 28.1 |
| 22 |  $MLYS | Mineralys Therapeutics, Inc. | $2.8M | 2.0% | +25% | — |
| 23 |  $SLN | Silence Therapeutics plc | $2.4M | 1.8% | -61% | — |
| 24 |  $NUVB | Nuvation Bio Inc. | $2.1M | 1.5% | NEW | 37.9 |
| 25 |  $WVE | Wave Life Sciences, Inc. | $1.9M | 1.4% | NEW | 7.5 |
| 26 |  $NKTR | NEKTAR THERAPEUTICS | $1.9M | 1.4% | NEW | 9.7 |
| 27 |  $SRRK | Scholar Rock Holding Corp | $1.7M | 1.2% | -46% | — |
| 28 |  $ELVN | Enliven Therapeutics, Inc. | $1.7M | 1.2% | NEW | — |
| 29 |  $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $1.5M | 1.1% | +0% | 71.4 |
| 30 |  $BEAM | Beam Therapeutics Inc. | $1.4M | 1.0% | -29% | 34.2 |
| 31 |  $SION | Sionna Therapeutics, Inc. | $1.4M | 1.0% | +150% | — |
| 32 |  $ORIC | Oric Pharmaceuticals, Inc. | $1.3M | 1.0% | +20% | — |
| 33 |  $NAMS | NewAmsterdam Pharma Co N.V. | $1.3M | 0.9% | +0% | — |
| 34 |  $VRTX | VERTEX PHARMACEUTICALS INC / MA | $1.2M | 0.9% | NEW | 75.4 |
| 35 |  $SPRY | ARS Pharmaceuticals, Inc. | $1.1M | 0.8% | NEW | 20.3 |
| 36 |  $MNPR | Monopar Therapeutics | $1.1M | 0.8% | NEW | — |
| 37 |  $ERAS | Erasca, Inc. | $751,120 | 0.6% | NEW | — |
| 38 |  $VERA | Vera Therapeutics, Inc. | $439,828 | 0.3% | -88% | — |
| 39 |  $IMTX | Immatics N.V. | $311,498 | 0.2% | -80% | — |
| 40 |  $MREO | Mereo BioPharma Group plc | $244,232 | 0.2% | NEW | — |
| 41 |  $GOSS | Gossamer Bio, Inc. | $134,972 | 0.1% | +0% | 8.2 |
New Positions (16)
$AGIO AGIOS PHARMACEUTICALS, INC.$6.1M$INSM INSMED Inc$5.5M$CRNX Crinetics Pharmaceuticals, Inc.$5.4M$TNXP Tonix Pharmaceuticals Holding Corp.$4.3M$BBIO BridgeBio Pharma, Inc.$4.3M$KURA Kura Oncology, Inc.$3.0M$CYTK CYTOKINETICS INC$2.8M$NUVB Nuvation Bio Inc.$2.1M$WVE Wave Life Sciences, Inc.$1.9M$NKTR NEKTAR THERAPEUTICS$1.9M$ELVN Enliven Therapeutics, Inc.$1.7M$VRTX VERTEX PHARMACEUTICALS INC / MA$1.2M$SPRY ARS Pharmaceuticals, Inc.$1.1M$MNPR Monopar Therapeutics$1.1M$ERAS Erasca, Inc.$751,120Exited Positions (12)
$PRAXPUT Praxis Precision Medicines, Inc.
$KALV KalVista Pharmaceuticals, Inc.
$FOLD AMICUS THERAPEUTICS, INC.
$VSTM Verastem, Inc.
$ARWR ARROWHEAD PHARMACEUTICALS, INC.
$MLTX MoonLake Immunotherapeutics
$ARDX ARDELYX, INC.
$CPRX CATALYST PHARMACEUTICALS, INC.
$LGND LIGAND PHARMACEUTICALS INC
$EWTX Edgewise Therapeutics, Inc.
$IDYA IDEAYA Biosciences, Inc.
$PTCT PTC THERAPEUTICS, INC.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Ishara Investments LP including:
Track Ishara Investments LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Ishara Investments LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Ishara Investments LP
13F Pro is an AI hedge fund tracker and stock research platform. For Ishara Investments LP (SEC CIK: 2111609), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Ishara Investments LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.